Literature DB >> 26944918

Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design.

Magdalena Dorywalska1, Russell Dushin2, Ludivine Moine2, Santiago E Farias1, Dahui Zhou2, Thayalan Navaratnam2, Victor Lui1, Adela Hasa-Moreno1, Meritxell Galindo Casas1, Thomas-Toan Tran1, Kathy Delaria1, Shu-Hui Liu1, Davide Foletti1, Christopher J O'Donnell2, Jaume Pons1, David L Shelton1, Arvind Rajpal1, Pavel Strop3.   

Abstract

The degree of stability of antibody-drug linkers in systemic circulation, and the rate of their intracellular processing within target cancer cells are among the key factors determining the efficacy of antibody-drug conjugates (ADC) in vivo Previous studies demonstrated the susceptibility of cleavable linkers, as well as auristatin-based payloads, to enzymatic cleavage in rodent plasma. Here, we identify Carboxylesterase 1C as the enzyme responsible for the extracellular hydrolysis of valine-citrulline-p-aminocarbamate (VC-PABC)-based linkers in mouse plasma. We further show that the activity of Carboxylesterase 1C towards VC-PABC-based linkers, and consequently the stability of ADCs in mouse plasma, can be effectively modulated by small chemical modifications to the linker. While the introduced modifications can protect the VC-PABC-based linkers from extracellular cleavage, they do not significantly alter the intracellular linker processing by the lysosomal protease Cathepsin B. The distinct substrate preference of the serum Carboxylesterase 1C offers the opportunity to modulate the extracellular stability of cleavable ADCs without diminishing the intracellular payload release required for ADC efficacy. Mol Cancer Ther; 15(5); 958-70. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26944918     DOI: 10.1158/1535-7163.MCT-15-1004

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  36 in total

1.  Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization.

Authors:  Alexei S Karpov; Cristina M Nieto-Oberhuber; Tinya Abrams; Edwige Beng-Louka; Enrique Blanco; Sylvie Chamoin; Patrick Chene; Isabelle Dacquignies; Dylan Daniel; Michael P Dillon; Lionel Doumampouom-Metoul; Nikolaos Drosos; Pavel Fedoseev; Markus Furegati; Brian Granda; Robert M Grotzfeld; Suzanna Hess Clark; Emilie Joly; Darryl Jones; Marion Lacaud-Baumlin; Stephanie Lagasse-Guerro; Edward G Lorenzana; William Mallet; Piotr Martyniuk; Andreas L Marzinzik; Yannick Mesrouze; Sandro Nocito; Yoko Oei; Francesca Perruccio; Grazia Piizzi; Etienne Richard; Patrick J Rudewicz; Patrick Schindler; Mélanie Velay; Kristine Venstrom; Peiyin Wang; Mauro Zurini; Marc Lafrance
Journal:  ACS Med Chem Lett       Date:  2019-12-03       Impact factor: 4.345

2.  Platinum-Triggered Bond-Cleavage of Pentynoyl Amide and N-Propargyl Handles for Drug-Activation.

Authors:  Bruno L Oliveira; Benjamin J Stenton; V B Unnikrishnan; Cátia Rebelo de Almeida; João Conde; Magda Negrão; Felipe S S Schneider; Carlos Cordeiro; Miguel Godinho Ferreira; Giovanni F Caramori; Josiel B Domingos; Rita Fior; Gonçalo J L Bernardes
Journal:  J Am Chem Soc       Date:  2020-06-09       Impact factor: 15.419

3.  Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.

Authors:  Steven Seaman; Zhongyu Zhu; Saurabh Saha; Xiaoyan M Zhang; Mi Young Yang; Mary Beth Hilton; Karen Morris; Christopher Szot; Holly Morris; Deborah A Swing; Lino Tessarollo; Sean W Smith; Sylvia Degrado; Dmitry Borkin; Nareshkumar Jain; Julia Scheiermann; Yang Feng; Yanping Wang; Jinyu Li; Dean Welsch; Gary DeCrescenzo; Amit Chaudhary; Enrique Zudaire; Kimberly D Klarmann; Jonathan R Keller; Dimiter S Dimitrov; Brad St Croix
Journal:  Cancer Cell       Date:  2017-04-10       Impact factor: 31.743

4.  The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass.

Authors:  Amita Datta-Mannan; Hiuwan Choi; David Stokell; Jason Tang; Anthony Murphy; Aaron Wrobleski; Yiqing Feng
Journal:  AAPS J       Date:  2018-09-25       Impact factor: 4.009

5.  Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cells.

Authors:  Sharad Sharma; Zhe Li; David Bussing; Dhaval K Shah
Journal:  Drug Metab Dispos       Date:  2020-02-21       Impact factor: 3.922

6.  Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release.

Authors:  Christopher Szot; Saurabh Saha; Xiaoyan M Zhang; Zhongyu Zhu; Mary Beth Hilton; Karen Morris; Steven Seaman; James M Dunleavey; Kuo-Sheng Hsu; Guo-Jun Yu; Holly Morris; Deborah A Swing; Diana C Haines; Yanping Wang; Jennifer Hwang; Yang Feng; Dean Welsch; Gary DeCrescenzo; Amit Chaudhary; Enrique Zudaire; Dimiter S Dimitrov; Brad St Croix
Journal:  J Clin Invest       Date:  2018-06-04       Impact factor: 14.808

7.  Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates.

Authors:  Alberto Dal Corso; Samuele Cazzamalli; Rémy Gébleux; Martin Mattarella; Dario Neri
Journal:  Bioconjug Chem       Date:  2017-07-06       Impact factor: 4.774

8.  Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis.

Authors:  Samuele Cazzamalli; Alberto Dal Corso; Fontaine Widmayer; Dario Neri
Journal:  J Am Chem Soc       Date:  2018-01-27       Impact factor: 15.419

9.  Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix.

Authors:  Rémy Gébleux; Marco Stringhini; Ruben Casanova; Alex Soltermann; Dario Neri
Journal:  Int J Cancer       Date:  2016-12-30       Impact factor: 7.396

10.  A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo.

Authors:  Alberto Dal Corso; Rémy Gébleux; Patrizia Murer; Alex Soltermann; Dario Neri
Journal:  J Control Release       Date:  2017-09-01       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.